Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS954 in Healthy Male and Female Participants
NCT06212804Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VIS-954 (7 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events and Wong-Baker FACES Pain Rating Scale at Day 29. Started Nov 2023; status: completed.
02
Drugs
VIS-954
Beyond the preview
Go deeper on NCT06212804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212804.